# Peptide Vaccination in Treating Patients With Esophageal Cancer

> **NCT00682227** · PHASE1 · UNKNOWN · sponsor: **University of Yamanashi** · enrollment: 10 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **BIOLOGICAL:** TTK, LY6K, and IMP-3 peptides

## Key facts

- **NCT ID:** NCT00682227
- **Lead sponsor:** University of Yamanashi
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-08
- **Primary completion:** 2008-12
- **Final completion:** 2009-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2008-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00682227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00682227, "Peptide Vaccination in Treating Patients With Esophageal Cancer". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00682227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*